Ovarian Cancer

Experts in gynecologic oncology review the case of a 71-year-old woman who is diagnosed with stage III, high-grade serous epithelial ovarian cancer, and comment on their approach to genetic testing in the frontline setting.

Dr Chirag A. Shah highlights novel emerging treatments in ovarian cancer and provides advice for community oncologists.

Chirag A. Shah, MD, details his personal clinical experience with using niraparib for ovarian cancer maintenance therapies.

An expert shares data from several clinical trials on the use of PARP inhibitors for maintenance therapies in ovarian cancer.

Dr Chirag A. Shah explains the front-line treatment options for ovarian cancer and the factors considered in choosing maintenance therapies.

A gynecologic oncologist discusses the importance of molecular testing in ovarian cancer and how it influences treatment selection.

Chirag A. Shah, MD, presents and reviews the case of a 59-year-old woman with ovarian cancer.

Promising results have been reported from the phase 1 study OCTAVE clinical trial.

Cecelia H. Boardman, MD, John K. Chan, MD, and Thomas C. Krivak, MD, provide insight on dosing schedules for niraparib maintenance in advanced ovarian cancer.

Thomas C. Krivak, MD, leads a discussion on guideline recommendations regarding the use of PARP inhibitors in newly diagnosed advanced ovarian cancer.

Experts in gynecologic oncology review data and clinical implications for the use of PARP inhibitors from the GOG-0218, SOLO-1, PRIMA, and PAOLA-1 trials in advanced ovarian cancer.

A panel of experts share insight on patient factors to consider when selecting first-line maintenance therapy for advanced ovarian cancer.

John K. Chan, MD, leads a discussion on the role of first-line maintenance therapy for advanced ovarian cancer and the standard of care first-line maintenance approaches for a patient with gBRCA2-mutated disease.

Cecelia H. Boardman, MD, John K. Chan, MD, and Ashley Farione, PA-C, discuss their treatment approach to genetic testing in patients with advanced ovarian cancer.

Dr Thomas C. Krivak reviews a case of a 59-year-old woman who has stage IV, high-grade serous epithelial ovarian cancer and discusses ASCO and NCCN guideline recommendations for germline/somatic tumor testing.

The FDA has granted a fast-track designation to the G-quadruplex stabilizer CX-5461 for BRCA1/2, PALB2, or HRD mutations in their breast or ovarian cancer.

In an interview with Targeted Oncology, Shannon N. Westin, MD, MPH, FACOG, reviewed the recent tweet chat around a high-grade epithelial ovarian cancer case.

During a live virtual event, Matthew L. Anderson, MD, PhD, discussed the results of the PRIMA study of niraparib in patients with wild-type and BRCA-mutated ovarian cancer.

During a live virtual event, Matthew L. Anderson, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for treating patients with advanced ovarian cancer using PARP inhibitors based on BRCA mutation status and other factors.

Rebecca C. Arend, MD, discusses the key unmet needs in the treatment landscape for platinum-resistant ovarian cancer.

Investigators reported meaningful pharmacodynamic and pharmacokinetic observations of BT5528 treatment, suggesting tumor penetration in a standard 3+ 3 dose-escalation trial.

Zai Lab has announced new findings from the phase 3 PRIME trial showing efficacy in progression-free survival in patients with platinum-sensitive ovarian cancer.

Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.

The PRESERVE-001 study has shown efficacy from ONC-392, a new anti-CTLA-4 antibody, as a monotherapy in patients with non–small cell lung cancer and ovarian cancer.

The combination of dendritic cell-based immunotherapy in the second-line of treatment for patients with ovarian cancer proves beneficial.